SINOMAB

SinoMab BioScience Limited
中國抗體製藥有限公司
(Incorporated in Hong Kong with limited liability)
(Stock code: 3681)

APPOINTMENT OF EXECUTIVE DIRECTOR

The board (the "**Board**") of directors (the "**Director(s)**") of SinoMab BioScience Limited (the "**Company**", together with its subsidiaries, the "**Group**") hereby announces that Ms. Fang LIANG ("**Ms. Liang**") has been appointed as an executive Director of the Company with effect from 3 July 2026.

Ms. Fang LIANG, aged 45, has been serving as the chief operating officer of our Company since 19 March 2026, and is primarily responsible for the overall R&D and business operations and strategic direction of the Group.

Ms. Liang has more than 20 years of experience in drug discovery, development, healthcare investment and biotech leadership. Prior to joining our Group, Ms. Liang served as executive director and chief strategy officer responsible for investor relations, financing, portfolio strategy & business development of Shanghai Argo Biopharmaceutical Co., Ltd. from January 2023 to June 2025. Previously, she served as senior vice president at Loyal Valley Capital from December 2020 to December 2022, where she led investments in multiple prominent biotech companies (Shanghai Argo Biopharmaceutical Co., Ltd., MediLink Therapeutics (Suzhou) Co., Ltd., Nanjing Leads Biolabs Co., Ltd. (the shares of which are listed on the Stock Exchange, stock code: 9887) and Hangzhou Sciwind Biosciences Co., Ltd.) and served as a non-executive board director for several portfolio companies. She also held senior management roles as vice president at GP Healthcare Capital from October 2018 to November 2020. Earlier in her career, Ms. Liang was an Associate Scientist at Novartis Institutes for Biomedical Research Co., Ltd from October 2008 to July 2017.

Ms. Liang holds a Master of Business Administration degree from Manchester University and a Bachelor of Science in Chemistry degree from Lanzhou University.

As at the date of this announcement, Ms. Liang is interested in 2,773,260 share awards pursuant to the share award scheme of the Company as her interest in the securities of the Company and its associated corporation within the meaning of Part XV of the Securities of Futures Ordinance (Chapter 571 of the Laws of Hong Kong) ("**SFO**").

Ms. Liang will enter into a letter of appointment with the Company, pursuant to which she will be appointed as an executive Director for an initial term of three years from the date of appointment, subject to re-election and retirement as required by the second amended and restated articles of association of the Company (the "**Articles**"). Ms. Liang will hold office until the first annual general meeting of the Company and shall then be eligible for re-election. No remuneration and/or director's fee will be paid to Ms. Liang in respect of her appointment as an executive Director. Under her existing employment contract, the remuneration currently payable to Ms. Liang in respect of her employment as the chief operating officer of the Company is RMB2,000,000 per annum, which was determined by reference to industry norm and market conditions and based on the services rendered to the Group, and, in addition, performance based discretionary bonus and shall be eligible to share incentive subject to internal approval. Ms. Liang will not be entitled to receive additional remuneration for serving as other roles in the Group.

Saved as disclosed above, as at the date of this announcement, Ms. Liang (i) is not interested or is not deemed to have any other interests or short positions in the shares or underlying shares of the Company within the meaning of Part XV of the SFO; (ii) is independent from and has no relationship with any Directors, senior management, substantial shareholders or controlling shareholders of the Company; (iii) has not held any other major appointments or qualifications or positions in the Company or other members of the Group; and (iv) has not held directorship in any other listed in public companies, the securities of which are listed on any securities market in Hong Kong or overseas, in the past three years. The Board is not aware of any other matters relating to the appointment of Ms. Liang that need to be brought to the attention of the shareholders of the Company, nor any information involved in any of the matters required to be disclosed pursuant to any of the requirements under Rule 13.51(2)(h) to (v) of the Listing Rules.

The Board is delighted to welcome Ms. Liang for joining the Company. The Board believes that Ms. Liang's expertise and experience will bring significant benefit to the Groups' long-term development in the future.

By Order of the Board
SinoMab BioScience Limited
Dr. Shui On LEUNG
Executive Director, Chairman and Chief Executive Officer

Hong Kong, 3 July 2026

As at the date of this announcement, the executive directors of the Company are Dr. Shui On LEUNG and Ms. Fang LIANG, the non-executive directors of the Company are Ms. Lei XUE, Ms. Xiaosu WANG and Dr. Jianmin ZHANG, and the independent non-executive directors of the Company are Mr. George William Hunter CAUTHERLEY, Mr. Ping Cho Terence HON, Dr. Chi Ming LEE, Ms. Chi Sau Giselle LEE and Mr. Nan SHEN.